Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G David Roodman

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 5, 2023
Doubling Down on Wnt Signaling to Overcome Myeloma Bone DiseaseJesús Delgado-Calle, G David Roodman
Cancer Treatment Reviews|October 30, 2007
RANK ligand as a therapeutic target for bone metastases and multiple myelomaG David Roodman, William C Dougall
Cancer Treatment and Research|March 27, 2004
MIP-1 alpha and myeloma bone diseaseG David Roodman, Sun Jin Choi
Annals of the New York Academy of Sciences|December 7, 2007
Perspective on the osteoclast: an angiogenic cell?Frank C Cackowski, G David Roodman
Best Practice & Research. Clinical Haematology|December 12, 2007
Pathophysiology of myeloma bone diseaseFlavia R Esteve, G David Roodman
Immunological Reviews|November 30, 2005
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myelomaLori A Ehrlich, G David Roodman
Journal of Bone Metabolism|July 16, 2014
Pathobiology of Paget's Disease of BoneDeborah L Galson, G David Roodman
Blood|August 19, 2006
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibitionNicola Giuliani, Vittorio Rizzoli, G David Roodman
Experimental Hematology|December 13, 2006
Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myelomaAlissa Huston, Jason Brown, G David Roodman
Archiv Der Pharmazie|September 13, 2007
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myelomaSuzanne Lentzsch, Gary Elliott, G David Roodman
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 5, 2023
Doubling Down on Wnt Signaling to Overcome Myeloma Bone DiseaseJesús Delgado-Calle, G David Roodman
Cancer Treatment Reviews|October 30, 2007
RANK ligand as a therapeutic target for bone metastases and multiple myelomaG David Roodman, William C Dougall
Cancer Treatment and Research|March 27, 2004
MIP-1 alpha and myeloma bone diseaseG David Roodman, Sun Jin Choi
Annals of the New York Academy of Sciences|December 7, 2007
Perspective on the osteoclast: an angiogenic cell?Frank C Cackowski, G David Roodman
Best Practice & Research. Clinical Haematology|December 12, 2007
Pathophysiology of myeloma bone diseaseFlavia R Esteve, G David Roodman
Immunological Reviews|November 30, 2005
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myelomaLori A Ehrlich, G David Roodman
Journal of Bone Metabolism|July 16, 2014
Pathobiology of Paget's Disease of BoneDeborah L Galson, G David Roodman
Blood|August 19, 2006
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibitionNicola Giuliani, Vittorio Rizzoli, G David Roodman
Experimental Hematology|December 13, 2006
Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myelomaAlissa Huston, Jason Brown, G David Roodman
Archiv Der Pharmazie|September 13, 2007
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myelomaSuzanne Lentzsch, Gary Elliott, G David Roodman
Pageof 15